RxDoctor Payments Data

James Hirschfeld, MD

Ophthalmology · Parsippany, NJNPI 1023022407

Payments from drug & device makers

$3,508in general payments, 2019–2025

Across 147 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$1K
  • Rxsight Inc$448
  • Lumenis BE Inc$382
  • Alcon$298
  • Bausch & Lomb Americas Inc.$267
  • Oyster Point Pharma, Inc.$155
  • plus $835 from 19 others

What the payments were for

  • Food & beverage$3,48899%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,508 in reported general payments places this provider in the 70th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$612,709
Medicare patients
686
Services billed
6,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod103$49,632
LumiganBimatoprost66$42,853
XiidraLifitegrast26$26,147
Lotemax SmLoteprednol Etabonate67$16,689
RestasisCyclosporine15$14,035
CombiganBrimonidine Tartrate/Timolol25$8,217
BromsiteBromfenac Sodium29$7,477
Travoprost40$6,645
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$5,246
Latanoprost385$5,018
TafluprostTafluprost/Pf19$4,582
MoxifloxacinMoxifloxacin Hcl158$4,333
Dorzolamide-TimololDorzolamide/Timolol/Pf14$3,682
Prednisolone Acetate103$2,958
Tobramycin-DexamethasoneTobramycin/Dexamethasone62$2,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$267$75,779129 claims
AbbVieLumigan, Restasis, Combigan$57$65,105106 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$82$16,68967 claims
Sun Pharmaceutical Industries Inc.Bromsite$1,123$7,47729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Parsippany

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →